Post by icemandios on Nov 29, 2018 13:59:45 GMT
PolarityTE Announces Recognition of SkinTE as Finalist for Fierce Innovation Awards Biotech Innovation
These awards, established by FierceBiotech and FiercePharma, recognize outstanding innovation that is transforming medicine. An expert panel of judges, comprised of industry leaders in the biotech field, review submissions to determine which companies and products demonstrate innovation that has the potential to make the greatest impact. Submissions are scored based on the following criteria: effectiveness, technical innovation, competitive advantage, financial impact and true innovation. The winner will be announced on December 13, 2018 with the publication of the Fierce Innovation Report – Life Sciences Edition 2018.
"We are honored that SkinTE has been named as a finalist in the Biotech Innovation category of the Fierce Innovation Awards. Though SkinTE has only been available to patients for less than a year, the selection as a finalist is credit to the impact it is having on patients and industry. We appreciate recognition of our work as we continue to deliver on the promise of regenerative medicine," said Denver M. Lough, MD, PhD, Chairman and Chief Executive Officer of PolarityTE.
PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. The PolarityTE platform technology begins with a small piece of the patient's own, or autologous, healthy tissue, rather than artificially manipulated individual cells. From this small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to enhance and stimulate the patient's own cells to regenerate the target tissues. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures with the patient's own tissue and uses the patient's own body to support the regenerative process to create the same tissue from which it was derived. PolarityTE's innovative method is intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing. Learn more at www.PolarityTE.com – Welcome to the Shift®.
SkinTE is a human cellular and tissue-based product derived from a patient's own skin intended for the repair, reconstruction, and replacement of skin tissue. SkinTE results have shown the regeneration of full-thickness (epidermis, dermis and hypodermis), functionally-polarized skin with all the appendages including hair and glands.
SkinTE is intended to be used by physicians or other appropriate healthcare providers for homologous uses of skin tissues/integument. Patients who have suffered from an event, disease, process or acquired deficit that results in the functional loss or void of skin/integument systems can receive SkinTE as an adjunct and/or in place of split-thickness skin grafting, full-thickness grafting, temporizing skin coverage and/or skin substitute products. SkinTE is for autologous use only. Aseptic technique during harvest and deployment of SkinTE is mandatory. SkinTE is marketed as an HCT/P regulated by the FDA solely under Section 361 of the Public Health Service Act and 21 CFR 1271.